A Rare Disease Patient That Does It All!

by | Dec 18, 2014 | 2 comments

Kim-Goodsell-990x670A movie script could not play out like this. There are very few occasions when a rare disease patient becomes the topic of a story that is truly uplifting. Often the stories are tragic or disheartening. That was not the case, however, with CMT patient Kim Goodsell.

Kim recently became the subject of a story by the acclaimed science writer Ed Yong that simultaneously appeared in National Geographic online ( as well as the Welcome Trust blog, Mosaic ( story/diy-diagnosis-how-extreme-athlete-uncoveredher-genetic-flaw). The article describes how Kim was a competitive triathlete until she was diagnosed with arrhythmogenic right ventricular cardiomyopathy (ARVC), predisposing her to sudden cardiac death. In the years that followed Kim’s motor skills became progressively compromised and thirteen years after her ARVC diagnosis, she was diagnosed with CMT 2B1, co-segregating with an Emery Driefuss Muscular Dystrophy (EDMD)-like myopathy. As unbelievable as it sounds, Kim had multiple rare diseases.

So Kim set out to learn as much as possible to understand whether her diseases were related. She eventually narrowed down the culprit to a gene called LMNA. She then had to convince scientists to dig deeper and went as far as funding the sequencing of the DNA of her LMNA gene. The results showed that Kim indeed had a mutation in LMNA. Kim ultimately wrote up a thesis on her whole experience and is trying to get her experience published. This unique ability to not only survive, but thrive, and drive research to diagnose the culprit for her own diseases has attracted interest from prominent scientists for several reasons. For one it shows how much a patient can do themselves when empowered to do so. And second, as a patient Kim knew more about her disease than anyone else including the specialists that looked into her diseases. CMT (and rare diseases in general) need patients like Kim that can make discoveries that could lead to a greater understanding of the disease. This inspirational story is not over and it will be fascinating to see what Kim does next on her voyage of rare disease discovery.

Thank you, Kim, for sharing your story with HNF…you are an inspiration!

Learn more on this topic

Related Blog Posts

Double Your Donation

Corporate matching gift programs are charitable giving programs setup by corporations in which the company matches donations made by employees to eligible nonprofit organizations. For example, if a donor works for Bank of America and donates $100 to the Hereditary Neuropathy Foundation, Bank of America will double the donation by also writing a check for $100.

Taking Matters Into Your Own Hands

Do you have a rare form of CMT?

We were contacted recently from a patient with CMT2D who was looking for advice on how to make a difference. Our recommendations for all people with an ultra-rare form of CMT who want to get involved:

Now GRIN is Accessible in 141 Different Languages!

Now GRIN is Accessible in 141 Different Languages!

The Global Registry for Inherited Neuropathies (GRIN) has implemented Google Translate. Why did we choose Google? Because Google is leading the way in teaching computers how to interpret meaning, avoiding the traditional method of decoding language.

Accelerating Patient Access to Investigational Drugs in 2015

Accelerating Patient Access to Investigational Drugs in 2015

Currently the FDA is working to update the process for physicians applying for accelerated patient access to investigational drugs, while the drug or biological product is being tested in clinical trials. This will also be important for the CMT community as clinical trials for this disease are being launched.

Do You Have Charcot-Marie-Tooth Type 4 (CMT4)? – We Need Your Help

Autosomal recessive demyelinating CMT4 patients present with earlyonset and slowly progressing symptoms. These include progressive distally accentuated weakness and atrophy of muscles in the lower limbs. In addition, patients may have weakness and atrophy of hands, sensory loss and pes cavus (high-arched feet), and walking difficulties. Further information on CMT4 can be found at Orphanet.

Hot Off the Press – Potential Treatment for CMT1A

Two recent publications from Pharnext describe a novel synergistic combination of 3 drugs (baclofen, naltrexone and sorbitol) and its effect on CMT1A both in the lab and in a phase II clinical trial. These 3 drugs already approved but for unrelated conditions, are combined at new optimal lower doses and under a new formulation. This novel potential therapeutic is called PXT-3003.

Support CMT Therapeutic Alliance

HNF has entered into a joint venture – the CMT Therapeutic Alliance – with a unique non profit organization (BioPontis Alliance for Rare Diseases) that brings professional drug discovery capabilities to translate our research results into potential treatments.

Scientific Advisory Board Meeting

Scientific Advisory Board Meeting

On the 7th of November we convened our scientific advisory board meeting at the HNF offices in NY. We have written a detailed review that has been published and captures all of the discussion and make this freely available to the scientific community.

Join the conversation

Leave a Comment


  1. Jeannie Hoots

    We are all individuals and each of us know what we feel, what hurts, what helps and the more of us that do what Kim has done the quicker we can find ways to help others. Gaining knowledge of the science behind CMT and other diseases mixed with each person’s day to day battles is the best medicine. Only we truly know how and what is going on in our bodies. Good luck and I look forward to seeing or hearing more soon.

  2. Marianne De Sterano-Hill

    It just goes to show you that knowledge is indeed power, and one person CAN make a difference! Kim, you rock!…. ….and inspire the rest of us to action!


Submit a Comment

Your email address will not be published. Required fields are marked *


Join for notifications on events, campaigns, & news